Generalized Pustular Psoriasis (GPP) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Generalized Pustular Psoriasis (GPP) – Drugs In Development, 2024 report and make more profitable business decisions.
Pustular psoriasis is a rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Generalized pustular psoriasis is often associated with metabolic syndrome and polyarthritis
The Generalized Pustular Psoriasis (GPP) drugs in development market research report provide comprehensive information on the therapeutics under development for Generalized Pustular Psoriasis (GPP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Generalized Pustular Psoriasis (GPP) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Generalized Pustular Psoriasis (GPP) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Generalized Pustular Psoriasis (GPP) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Generalized Pustular Psoriasis (GPP) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Generalized Pustular Psoriasis (GPP) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AnaptysBio IncBoehringer Ingelheim International GmbH
Huabo Biopharm (Shanghai) Co Ltd
Inmagene Biopharmaceuticals Ltd
JiangSu Qyuns Therapeutics Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Psoriasis reports